• Publications
  • Influence
ONECUT2 is a driver of neuroendocrine prostate cancer
TLDR
ONECUT2 is reported to drive NEPC tumorigenesis via regulation of hypoxia signaling and tumorHypoxia directed therapy to be effective in NEPC is found, highlighting the potential of Hypoxia-directed therapy for NEPC patients.
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
TLDR
This study identifies the flavoprotein P450 (cytochrome) oxidoreductase (POR) as a potential predictive biomarker of HAP sensitivity that should be explored during the clinical development of SN30000, TH-302, and other hypoxia-directed agents.
CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration
TLDR
Binformatic analyses revealed that CHCHD2 is consistently coamplified with EGFR in non–small cell lung carcinoma (NSCLC) and EGFR protein expression levels were positively correlated and upregulated relative to normal lung in NSCLC tumor-derived xenografts.
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
TLDR
It is reported that genetic or pharmacological inhibition of GLUT1 with BAY-876 impairs the growth of a subset of TNBC cells displaying high glycolytic and lower oxidative phosphorylation (OXPHOS) rates.
Isotopologous Organotellurium Probes Reveal Dynamic Hypoxia In Vivo with Cellular Resolution.
Changes in the oxygenation state of microenvironments within solid tumors are associated with the development of aggressive cancer phenotypes. Factors that influence cellular hypoxia have been
...
...